Clinical Trials
Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA
Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...
October 13, 2026 | News
Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy
Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening...
October 13, 2026 | News
12 APAC-Originated Programmes to Watch at ESMO 2026
When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...
October 13, 2026 | News
Innovent’s SYCUME Meets Primary Endpoint in Phase III Trial for Inactive Thyroid Eye Disease in China
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 12, 2026 | News
Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...
October 12, 2026 | News
Resonant Clinical Solutions and Haier Biomedical Launch Eco-Friendly Centrifuge for Clinical Trials
Resonant Clinical Solutions – a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lif...
October 09, 2026 | News
OncoBayes’ OB-001 Shows Potential to Overcome ADC Resistance and Boost Brain Penetration of Cancer Drugs
OncoBayes, a privately held clinical-stage pharmaceutical company, announced the successful completion of preclinical work with OB-001, demonstrating the p...
October 08, 2026 | News
Celaid Therapeutics Raises $2.6M to Advance CLD-001 Towards US Clinical Trials
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 Celaid Therapeutics Inc...
October 06, 2026 | News
CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...
October 06, 2026 | News
Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...
October 06, 2026 | News
Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...
October 05, 2026 | News
Ractigen Reports First Human Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in hu...
October 05, 2026 | News
Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma
Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...
October 02, 2026 | News
Suvoda Expands Unified Clinical Trial Platform With AI-Powered Capabilities
- Suvoda, a global clinical trial technology company, announced a new release of important advancements since unifying the market-leading Suvoda...
October 02, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
